Many successful vaccines induce persistent antibody responses that can last a lifetime. The mechanisms by which they do so remain unclear, but emerging evidence indicates that they activate dendritic cells via Toll-like receptors (TLRs) 1, 2 . For example, the yellow fever vaccine YF-17D, one of the most successful empiric vaccines ever developed 3 , activates dendritic cells via multiple TLRs to stimulate proinflammatory cytokines 4, 5 . Triggering specific combinations of TLRs in dendritic cells can induce synergistic production of cytokines 6 , which results in enhanced T-cell responses, but its impact on antibody responses remain unknown. Learning the critical parameters of innate immunity that program such antibody responses remains a major challenge in vaccinology. Here we demonstrate that immunization of mice with synthetic nanoparticles containing antigens plus ligands that signal through TLR4 and TLR7 induces synergistic increases in antigen-specific, neutralizing antibodies compared to immunization with nanoparticles containing antigens plus a single TLR ligand. Consistent with this there was enhanced persistence of germinal centres and of plasma-cell responses, which persisted in the lymph nodes for .1.5 years. Surprisingly, there was no enhancement of the early short-lived plasma-cell response relative to that observed with single TLR ligands. Molecular profiling of activated B cells, isolated 7 days after immunization, indicated that there was early programming towards B-cell memory. Antibody responses were dependent on direct triggering of both TLRs on B cells and dendritic cells, as well as on T-cell help. Immunization protected completely against lethal avian and swine influenza virus strains in mice, and induced robust immunity against pandemic H1N1 influenza in rhesus macaques.
We designed a nanoparticle-based vaccine, similar to a virus in size and composition. A biodegradable synthetic polymer, poly(D,L-lacticco-glycolic acid) (PLGA) 7 , was used to synthesize ,300-nM-sized nanoparticles containing the TLR ligands MPL (TLR4 ligand), R837 (TLR7 ligand), or both ligands, together with an antigen (Supplementary Fig. 1 ). Immunization of mice with nanoparticles containing MPL and R837 (PLGA(MPL1R837)) plus antigen induced enhanced antibody and T-cell responses, compared to immunization with soluble antigen plus MPL and R837 (data not shown). Consistent with recent observations 8, 9 , delivery of antigen and TLR ligands in separate nanoparticles induced a stronger antibody response than delivery of both in the same nanoparticle ( Supplementary Fig. 2 ). Initially, cohorts of C57BL/6 mice were immunized with nanoparticles containing chicken ovalbumin (OVA) alone (PLGA(OVA)), or (PLGA(OVA)) together with PLGA(MPL), PLGA(R837), or (PLGA(MPL1R837). OVA emulsified in alum was used as a control. Immunization with PLGA(MPL) or PLGA(R837) plus nanoparticles containing 50 mg or 10 mg of OVA ( Supplementary Figs 3a, 4a ), induced enhanced OVA-specific antibody titres after immunization. Notably, there was a synergistic enhancement of the antibody titres in mice that received PLGA(MPL1R837) ( Supplementary Figs 3a, 4a ). Secondary immunization with the same immunogen 5 weeks later markedly increased titres in all groups, with the synergy effect with PLGA(MPL1R837) still evident, especially at the lower 10 mg dose (Supplementary Figs 3b, 4b). Thus, in all following experiments we used 10 mg of antigen. In addition to OVA, we also used other antigens including the protective antigen (PA) from Bacillus anthracis 10 ( Supplementary Fig. 5 ), and haemagglutinin (HA) from avian influenza H5N1 virus 11 (Fig. 1 ). As observed with OVA, there was a synergistic enhancement in the antigen-specific antibody responses after primary and secondary immunization of mice with PLGA(MPL1R837) plus PLGA(PA) (Supplementary Fig. 5a, b ), or PLGA(HA) ( Fig. 1a, b ).
The avidity of antigen-antibody binding is one index of the quality of the antibody response 12 . We used a surface plasmon resonance (SPR) assay to assess avidity. Sera from mice immunized with PLGA(MPL1R837) plus PLGA(HA) gave the highest binding response ( Fig. 1c ). The slower dissociation and higher association rates indicate that immunization with PLGA(MPL1R837) plus PLGA(HA) induced a more enhanced high-affinity antibody response than that induced by PLGA(MPL) or PLGA(R837) plus PLGA(HA). A similar trend was also observed with PA as an antigen ( Supplementary Fig. 5c ). Consistent with the effects on enzyme-linked immunosorbent assay (ELISA) titres and avidity, mice immunized with PLGA(MPL1R837) plus PLGA(HA) had the greatest neutralization antibody titres ( Fig. 1d ).
Next we assessed the mechanism by which PLGA(MPL1R837) induced synergistic responses. PLGA(MPL1R837) enhanced the secretion of proinflammatory cytokines by dendritic cells in vitro, compared to PLGA(MPL) or PLGA(R837) ( Supplementary Fig. 6a ). Further, in vivo depletion of dendritic cells in CD11c-DTR transgenic mice 13 , or Langerhans cells using the Langerin-DTR mice 14 , resulted in diminished antibody titres ( Supplementary Fig. 6b , c). These data demonstrate a critical role for dendritic cells in mediating the antibody response to immunization with PLGA(MPL1R837). Signalling via TLR4 and TLR7 is dependent on the adaptor proteins MyD88 or TRIF (also known as TICAM-1); MPL is reported to signal predominantly via TRIF 15 . Both MyD88 and TRIF were required for antibody responses stimulated by PLGA(MPL1R837) plus PLGA(OVA) (Supplementary Fig. 7) .
B cells express and respond to TLRs 16, 17 . Thus, we determined whether direct triggering of TLRs on B cells was essential for antibody responses. In vitro stimulation of naive splenic B cells with PLGA(MPL1R837) synergistically enhanced B-cell proliferation relative to stimulation with PLGA(MPL) or PLGA(R837) (data not shown). To assess this effect in vivo, mice lacking B cells (mMT mice) were reconstituted with B cells from wild-type mice, or MyD88 2/2 or Trif 2/2 mice, and then immunized with PLGA(MPL1R837) plus PLGA(OVA) ( Fig. 2a ). In mMT mice reconstituted with wild-type B cells immunization induced asynergisticenhancementof antibodyresponses( Fig.2b ).However,mMT mice reconstituted with MyD88 2/2 or Trif 2/2 B cells had diminished antibody titres ( Fig. 2c ), demonstrating that direct TLR triggering on B cells was required for stimulation of antibody responses. We determined then whether the synergy was dependent on co-expression of TLR4 and TLR7 on the same B cell, or whether there could be complementation between B cells lacking different TLRs. We thus transferred B cells from Tlr4 2/2 mice, or Tlr7 2/2 mice, or a 1:1 mixture of B cells from Tlr4 2/2 and Tlr7 2/2 mice into mMT mice. Immunization with PLGA(MPL1R837) and PLGA(OVA) demonstrated a requirement for co-expression of both TLRs on the same B cell ( Fig. 2d ).
Lastly, TLR activation of dendritic cells is known to stimulate antigen-specific CD4 1 T-helper cells, which are essential for induction of antibody responses 18 . Depletion of CD4 1 T-helper cells before immunization diminished antibody responses ( Supplementary Fig. 8 ). Consistent with this, immunization with PLGA(MPL1R837) and PLGA(OVA) resulted in an enhanced antigen-specific CD4 1 T-cell response ( Fig. 2e ). Interestingly, we observed ( Fig. 2f ) that OVA-specific CD4 1 T-helper cell responses were substantially reduced in mMT mice transferred with MyD88 2/2 or Trif 2/2 B cells (in which the antibody responses were severely compromised; Fig. 2c ), indicating a requirement for activated B cells in mediating enhanced activation of CD4 1 T-helper cells, as demonstrated previously 19 .
Antibody responses develop along two anatomically and functionally distinct pathways 20 . The extrafollicular pathway rapidly generates shortlived, antibody-producing cells (plasma cells), and the germinal-centre pathway generates memory B cells and long-lived plasma cells that secrete high-affinity antibody 20 . We determined whether immunization with nanoparticles containing different adjuvants differentially regulated the two pathways. Thus, mice immunized with the different adjuvants were killed at day 7, lymph nodes isolated and the presence of antibody-producing plasma cells evaluated by immunohistology. There was no apparent difference in the IgG 1 plasma cells, at day 7, between mice immunized with various adjuvants ( Supplementary  Fig. 9 ). We investigated also the kinetics of germinal-centre formation following immunization. Notably, mice immunized with both TLR ligands had a greatly enhanced and sustained germinal-centre response compared to those immunized with a single TLR ligand, (Fig. 3a, b and Supplementary Fig. 9 ). At day 28 there were approximately 10-12 germinal centres per lymph node and at day 42 there were about 6 germinal centres per lymph node, significantly higher than the numbers observed in lymph nodes of mice immunized with single TLR ligands ( Fig. 3a, b ). By 8 weeks after immunization the numbers of germinal centres were still substantially higher in the PLGA(MPL1R837) group than in the other groups (Fig. 3b ). This demonstrates that PLGA(MPL1R837) preferentially enhances the germinal-centre pathway.
Further, assessment of antigen-specific IgG-secreting plasma cells by the enzyme-linked immunosorbent spot (ELISPOT) assay, indicated no differences in the numbers of plasma cells at day 7 in the 
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MPL alone versus MPL1R837 groups ( Fig. 3c ). At day 28 there were enhanced numbers of plasma cells in the PLGA(MPL1R837) group relative to single TLR-ligand groups. Secondary immunization with the same antigen plus adjuvant resulted in a profoundly enhanced and sustained memory response in the PLGA(MPL1R847) group (Fig. 3c ). Notably, there was a persistent plasma-cell response in the lymph node for .1.5 years. Interestingly, there was no corresponding enhancement in the numbers of antigen-specific plasma cells in the bone marrow-a known destination for plasma cells 21 -in the PLGA(MPL1R837) group relative to the single TLR-ligand groups (data not shown). This demonstrates that immunization with PLGA(MPL1R837) preferentially enhances memory B-cell generation. Consistent with this, fluorescence-activated cells sorting (FACS) analysis 22 revealed enhanced numbers of isotype-switched, antigen-specific B cells in the PLGA(MPL1R837) group relative to the PLGA(MPL) or PLGA(R837) groups during the memory phase after a secondary boost, but no such enhancement early during the primary response ( Supplementary Fig. 10 ).
The effects of PLGA(MPL1R837) on the germinal-centre pathway might have occurred via early programming of antigen-specific B cells, or as a result of the continued presence of antigen and/or adjuvant. To determine whether there was any early programming of B cells, we isolated isotype-switched, antigen-experienced B cells by FACS at 7 days after immunization with nanoparticles containing various adjuvants plus OVA, and performed microarray analyses to assess their molecular signatures. Notably, there was a great enrichment for genes normally expressed in memory B cells 23 , in the cells isolated from mice immunized with PLGA(MPL1R837) plus PLGA(OVA); in contrast, in cells isolated from mice immunized with either PLGA(MPL) or PLGA(R837) plus PLGA(OVA), there was no such enrichment ( Supplementary Fig. 11a-c) . Such genes included Bcl2, Bcl11a, Tank, several type-I interferon (IFN)-related genes, Plcg2 and Cd38, which are known to have key roles in memory B-cell formation, and several genes that regulate the survival, proliferation and differentiation of germinal-centre B cells, such as Il17ra, Il18r1, Pax5, Ifngr2, Bcor and Ikzf1 ( Supplementary Fig. 11a, b) . These data indicate that immunization with antigen and MPL1R837 stimulates early programming to the germinal-centre/memory pathway.
Next we determined whether immunization also enhanced antigenspecific memory T-cell responses. There was a synergistic enhancement of OVA-specific IFN-c-producing CD4 1 T-helper cell responses at 8 weeks after secondary immunization ( Supplementary Fig. 12a, b ), but not at days 7 or 14 after primary immunization (data not shown), indicating a preferential effect on the generation of memory T cells. Similar results were observed in mice immunized with HA and PA antigen, even 1.5 years after immunization ( Supplementary Fig. 12c-f ). PLGA(MPL1R837) immunization also enhanced the antigen-specific CD8 1 T-cell responses. Although no synergistic enhancement was observed in the frequencies of IFN-c producing, OVA-specific CD8 1 T cells at day 7 after primary immunization, there was an increase at day 7 after secondary immunization ( Supplementary Fig.  13 ). Polyfunctional T cells secreting multiple cytokines such as IFN-c, TNF-a and IL-2 have been implicated in mediating enhanced protection 24 . We also observed enhanced numbers of triple (IFN-c, TNF-a and IL-2) and double cytokine (IFN-c, IL-2) producing CD8 1 T cells in mice immunized with PLGA(MPL1R837) ( Supplementary Fig.  14a , b). Thus, PLGA(MPL1R837) enhances the magnitude and quality of the antigen-specific memory CD4 1 and CD8 1 T cells. To assess the relevance of enhanced B-and T-cell responses for protective immunity, we evaluated efficacy of these vaccines in mediating protection in mice, against the 2009 pandemic H1N1 influenza A virus 11 ( Supplementary Figs 15, 16 ) and the H5N1 avian influenza virus 11, 25 ( Supplementary Fig. 17 ). In each case, there was enhanced antigenspecific humoral immunity and survival against lethal infection of mice ( Supplementary Figs 15-17 ).
Finally, we assessed the immunogenicity of PLGA(MPL1R837) in non-human primates. In humans and non-human primates, unlike in mice, TLR7 is selectively expressed on plasmacytoid dendritic cells, and not on myeloid dendritic cells 2 . As multiple dendritic-cell subsets seem to be involved in the stimulation of antibody responses by PLGA(MPL1R837) ( Supplementary Fig. 6b , c), we used R848, which signals through both TLR7 and TLR8 2, 26 . Further, in humans, although naive B cells do not express TLRs 4, 7 or 8, activated B cells including plasma cells upregulate and respond to these TLRs 27 . Current human monovalent vaccines against H1N1 influenza contain 15 mg of HA (effectively 45 mg of whole inactivated virus (WIV)) 28 . We therefore used 50 mg of WIV (,16 mg HA), as well as a fivefold lower dose (,3 mg HA), with and without adjuvant, to determine whether there was a dose-sparing effect. Four cohorts of four rhesus macaques per cohort were immunized subcutaneously with the indicated doses of WIV, with or without PLGA(MPL1R837) or PLGA(MPL1R848) (Fig. 4a) . After a single immunization with 10 mg or 50 mg of WIV without any adjuvants, there was no detectable antibody response ( Fig. 4b-d ). In contrast, adjuvanting with PLGA(MPL1R848) 
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induced robust antibody responses, as early as 2 weeks (Fig. 4b-d ). Immunization with PLGA(MPL1R837) yielded enhanced binding antibodies, but had more modest effects on HA inhibition and neutralization titres ( Fig. 4b-d) . Notably, the magnitude of HA inhibition and neutralization titres 28 days after a single immunization with PLGA(MPL1R848) was much greater than 1/40, considered the correlate of protection against influenza in humans ( Fig. 4c, d) 29 . There was at least a fivefold dose-sparing effect, as 10 mg of antigen plus PLGA(MPL1R848) yielded a much greater response than that induced by 50 mg of antigen alone (Fig. 4b-d ). Secondary immunizations enhanced the antibody responses in all of the groups, and although PLGA(MPL1R848) still induced the strongest response, PLGA(MPL1R837) also induced responses greater than that required for protection ( Fig. 4c, d) . Further, the dose-sparing effect was still evident after secondary immunization ( Fig. 4b-d ).
Here we have described a nanoparticle-based vaccine that resembles a virus in size and composition, and that recapitulates the immunogenicity of live viral vaccines 5 . A notable feature of the immune 
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response stimulated by this vaccine is in the induction of long-lived germinal centres and persistent antigen-specific B-and T-cell responses, similar to that seen with viral infections 30 . Importantly, although all TLR ligands stimulate primary antibody responses, the combined TLR4 and TLR7 stimulus enhances the germinal-centre pathway of memory B-cell formation and long-lived plasma-cell responses, far more efficiently than stimulation with single TLR ligands ( Supplementary Fig. 18 ). The molecular signatures of antigenactivated B cells isolated early after immunization indicates early programming towards a quasi memory state ( Supplementary Fig. 11 ), but it is also likely that persistent antigen/adjuvants, as evidenced by persistent immune complexes in germinal centres (Fig. 3) , have a role. A curious aspect of our data is the requirement for the TLR ligands and antigens to be delivered on two separate particles, consistent with other studies 8, 9 . From a practical perspective, this offers flexibility in coupling a generic adjuvant-containing particle with another particle containing antigen from any pathogen. Further, as each of the components of this vaccine (MPL, R837, PLGA) have been licensed for human use, this vaccine formulation may provide a universal platform for vaccine design against pandemics and emerging infections.
METHODS SUMMARY
Synthesis and characterization of nanoparticles. Antigens were encapsulated in PLGA nanoparticles using a water in oil in water (w/o/w) emulsion technique. MPL was encapsulated in PLGA formulations using an oil in water (o/w) single emulsion process as described before with slight modifications 8 . Sizing of the nanoparticles was conducted using a dynamic light scattering, and protein loading was assessed as described before 31 .
Immunization of mice and non-human primates. Eight-to-twelve week old BALB/c or C57BL/6 mice (Charles River) were immunized with 10 mg of antigen encapsulated in nanoparticles suspended in 200 ml of PBS subcutaneously at the base of the tail. Ten-to-thirteen year old female Rhesus Macaques (7-10 kg) were used and were immunized subcutaneously in the right leg. All procedures were performed in accordance with the Emory School of Medicine Institutional Animal Care and Use Committee guidelines. Antigen-antibody affinity binding analysis. SPR binding measurements were carried out on a BIAcore 3000 instrument (BIAcore/GE Healthcare). H5N1 microneutralization assays. This was performed as described previously 25 . B-cell ELISPOT. 1 3 10 6 lymph node cells were serially diluted and cultured overnight in duplicate wells of OVA-coated nitrocellulose-lined 96-well plates (Millipore). Cells were discarded and wells were treated with biotinylated goat anti-mouse total IgG (Southern Biotech) in PBS/0.5% Tween-20 plus 1% FBS for 1.5 h at room temperature (25 uC) . Wells were washed and treated with streptavidin alkaline phosphatase (Vector Labs) for another 1.5 h at room temperature. Finally, NBT/BCIP colorimetric substrate for alkaline phosphatase was added to the wells and the reaction was stopped after visualization of purple coloured spots. Affymetrix GeneChip analysis. Total RNA from sorted B cells was purified using Trizol (Invitrogen). All RNA samples were checked for purity and for integrity and amplified, processed through EXON Module, fragmented and labelled. Labelled targets hybridized to GeneChip Mouse Gene 1.0ST arrays (Affymetrix). 
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METHODS
Encapsulation of antigens and TLR ligands in nanoparticles. Antigens were encapsulated in PLGA nanoparticles using a water in oil in water (w/o/w) emulsion technique. Briefly, 200 ml of protein solution (PBS 1 0.5% polyvinyl alcohol (PVA) as an excipient (Sigma Aldrich)), OVA grade VI (Sigma Aldrich) at 50 mg ml 21 , Bacillus anthracis PA (List Laboratories) at 15 mg ml 21 , and A/Vietnam/ 1203/2004 specific haemagglutinin protein (H5HA; affinity chromatography purified from 293 HEK cells) at 15 mg ml 21 were homogenized with 10% w/v PLGA (RG502H, Bohreinger Ingelheim) in dichloromethane (200 mg in 2 ml) with the Powergen homogenizer (Fisher Scientific) at speed 5 for 1.5 min. The water in oil emulsion (w/o) was then added to 15 ml of 5% w/v solution of PVA for the second emulsion step identical to the first emulsion process described earlier, at speed 5. The water in oil in water (w/o/w) double emulsion was then subjected to solvent evaporation for 4 h at room temperature (25 uC) . MPL was encapsulated in PLGA formulations using an oil in water (o/w) single emulsion process as described before with slight modifications 8 . MPL (detoxified lipid A, Avanti Lipids) was dissolved in chloroform at 5 mg ml 21 and TLR7 ligand R837 (Invivogen) was dissolved at 10-20 mg ml 21 in DMSO with heating. R848 was dissolved at 12.5 mg ml 21 in dichloromethane. MPL, 0.5 ml at 5 mg ml 21 was added to 200 mg of PLGA polymer dissolved in 2.0 ml of dichloromethane. For particles containing both MPL and R837, 0.5 ml or 5 mg of R837 in DMSO was added to the mixture of PLGA and MPL. For particles containing both MPL and R848, 8 mg of R848 in dichloromethane was added to the mixture of PLGA and MPL. For particles used in non-human primate studies, 0.1 ml of 5 mg ml 21 MPL, 0.5 ml or 10 mg of R837 and 12.5 mg of R848 was added to 200 mg of PLGA polymer in 2.0 ml of dichloromethane. The organic phase containing PLGA with MPL and/or R837 or R848 was homogenized with 15 ml of a 5% w/v PVA solution for 2 min using a speed setting 6 at room temperature. The oil in water emulsion (o/w) was then added to 85 ml of a 5% w/v solution of PVA surfactant to evaporate the organic solvent for 4 h at room temperature. The nanoparticles formed were centrifuged at 3,500g for 20 min and washed with 50 ml of 0.2-mm filter sterilized, deionized water 3 times. Nanoparticles were snap frozen in liquid nitrogen and lyophilized using a Freezone 2.5L benchtop lyophilizer (Labconco). Nanoparticle characterization. Sizing of the nanoparticles was conducted using a dynamic light scattering based sizer (90PLUS) from Brookhaven Instruments. Sizes are represented as the mean diameter of the volume average size distribution 6 standard deviation of different batches. Protein encapsulation levels were estimated as described before using a BCA assay (Pierce Biotechnology) 31 . UV-Vis scan using a Cary Win50 UV-Vis spectrophotometer yielded a peak absorbance for R837 at 325 nm (327 nm for R848) and encapsulation was estimated using a standard curve of R837 or R848 in DMSO and NaOH/SDS. MPL encapsulated in nanoparticles was used in splenic dendritic-cell stimulation experiments with known concentrations of soluble MPL yielding identical cytokine production and estimated at 100% encapsulation efficiency. Mouse dendritic cell culture. CD11c 1 dendritic cells were isolated from spleens of naive C57BL/6 mice. Spleens were digested with collagenase type IV (Worthington Chemicals), and CD11c 1 cells were enriched by positive selection using anti mouse CD11c magnetic beads according to manufacturer's instructions (Miltenyi Biotech). Dendritic cells (1 3 10 6 cells ml 21 ) were cultured in 48-well culture plates with PLGA-encapsulated TLR ligands for 24 h. Mice. Il6 2/2 and Ticam1 1ps2/lps2 strains were obtained from Jackson Labs. Ifnar 2/2 strain was obtained from S. Speck; MyD88 2/2 and Tlr7 2/2 from S. Akira; Tlr4 2/2 from K. Kobayashi. Immunization of mice and non-human primates. Eight-to-twelve week old BALB/c or C57BL/6 mice (Charles River Laboratories) were immunized with 10 mg of antigen in nanoparticles (suspended in 200 ml of PBS) subcutaneously at the base of the tail. TLR ligands were co-delivered with protein-encapsulated nanoparticles. Three milligrams of PLGA particles containing MPL, R837 or MPL1R837 containing 37.5 mg of MPL and 60 mg of R837 were used. Imject Alum (Pierce/ThermoScientific) was used to adsorb protein at a 1:1 volume ratio as per the manufacturer's instructions. Mice were bled via the lateral tail vein at regular intervals after primary and secondary immunizations and serum was isolated for analysis of antibody responses by ELISA assays. CD11c 1 DTR mice 13 were immunized 24 h after dendritic-cell depletion. Langerin-DTR mice 14 were immunized 3 weeks after depletion, when there is replenishment of Langerin 1 dendritic cells in the dermis and lymph nodes, but not in the epidermis 32 . CD4 1 T cells were depleted with an anti-mouse CD4 1 antibody (clone GK1.5, provided by R. Mittler) injected at 250 mg per mouse as described 33 . Ten-to-thirteen year old female Rhesus Macaques (7-10 kg) were used. Animals were immunized subcutaneously in the right leg. All animal procedures were performed in accordance with guidelines established by the Emory School of Medicine Institutional Animal Care and Use Committee Guidelines.
Antibody ELISA. Ninety-six-well Nunc maxisorp plates were coated with 100 ml of 20 mg ml 21 of OVA, 1 mg ml 21 of PA or 0.5 mg of H5HA protein overnight at 4u C. Plates were washed 3 times with PBS/0.5% Tween-20 using a Biotek auto plate washer and blocked with 200 ml of 4% non-fat dry milk (Biorad) for 2 h at room temperature. Serum samples from immunized mice at the indicated time points were serially diluted in 0.1% non-fat dry milk in PBS/0.5% Tween-20 and incubated on blocked plates for 2 h at room temperature. Detection antibodies were obtained from Southern Biotech. Wells were washed and incubated with anti-mouse IgG2c-HRP (horseradish peroxidase) conjugate (1:2,000), anti-mouse IgG2b-biotin conjugate (1:2,000), anti-mouse IgG1-HRP conjugate (1:5,000) and streptavidin-HRP conjugate (1:5,000) in PBS/0.5% Tween-20 for 2 h at room temperature. Plates were washed and developed using 100 ml per well of tetramethylbenzidine (TMB) substrate (BD Biosciences) and stopped using 2N H 2 SO 4 . Plates were analysed using a BioRad plate reading spectrophotometer at 450 nm with correction at 595 nm. Antibody titres were represented as serum reciprocal dilution yielding a $0.1 optical density (OD) value at 450 nm. Antibody levels (ng ml 21 ) in H1N1 WIV-immunized mice were assayed as previously described 34 .
To analyse WIV-specific antibody levels in rhesus macaques, the assay was performed as described for mice. A capture rhesus IgG (clone SB108A) was used to establish a standard curve with the rhesus IgG standards (catalogue no. 0135-01; Southern Biotech). 2 mg ml 21 of WIV was used to coat Nunc maxisorp plates overnight and plates were blocked with 4% non-fat dry milk. Rhesus plasma samples were used at appropriate dilutions for prime and boost and incubated for 2 h at room temperature. Plates were washed 53 with PBS/0.5% Tween-20 using an automated plate washer and a goat anti-rhesus HRP was used at 1:4,000 dilution for 1 h at room temperature, washed and developed with TMB substrate. Antibody concentrations were calculated from the IgG standard curves and represented as mg per ml. BIAcore assay. SPR binding measurements were carried out on a BIAcore 3000 instrument (BIAcore/GE Healthcare), as described previously 35 . Serum samples were injected at a 1:50 dilution in PBS for 5 min at a flow rate of 10 ml min 21 . Binding to the negative control rPA surface was subtracted from each sample curve and binding response was measured at 15 and 500 s after the end of the injection. As a measure of antigen-specific antibody-binding avidity, maximal response unit (binding RU) and dissociation rates were measured. Maximal binding RU was measured after subtraction of non-specific signal on the control surface at 15 s post-injection and normalized dissociation was calculated as a ratio of late-to-early binding responses over a dissociation phase of 500 s. Following each injection cycle, chip surfaces were regenerated with a short injection of 25 mM NaOH. H5N1 microneutralization assays. Serum samples from H5HA-immunized mice were tested for their ability to neutralize a recombinant (6:2) A/PR/8/34 influenza A virus expressing the A/Vietnam/1203/2004 H5HA and N1NA in cell culture in vitro as described previously 25 . Histology and immunofluorescence. Draining inguinal lymph nodes were isolated and snap frozen in moulds containing OCT medium, dropped into 2-methyl butane cooled with liquid nitrogen. Frozen lymph nodes were sectioned at 5 mm, fixed in ice-cold acetone for 10 min, air dried and stored at 280u C. Sections were fluorescently stained with Dylight488-labelled anti-mouse total IgG (Jackson Immunoresearch), Alexa647-labelled anti-mouse B220 or GL-7 (Ebioscience), followed by Alexa555-conjugated streptavidin (Invitrogen). Fluorescent images were captured using the 35 and 320 objectives on a Zeiss Axioscope (Carl Zeiss). B-cell ELISPOT. 1 3 10 6 lymph node cells were serially diluted and cultured overnight in duplicate wells of OVA-coated nitrocellulose-lined 96-well MAHA ELISPOT plates (Millipore). Cells were discarded and wells were treated with biotinylated goat anti-mouse total IgG (Southern Biotech) in assay buffer (PBS/0.5% Tween-20 11% FBS) for 1.5 h at room temperature. Wells were washed and treated with streptavidin alkaline phosphatase (Vector Labs) at 1:500 for 1.5 h at room temperature. NBT/BCIP colorimetric substrate for alkaline phosphatase was added to the wells and the reaction was stopped after visualization of purple coloured spots. Number of ELISPOTS per well were counted using an ImmunoSpot ELISPOT reader and represented as number of ELISPOTS (antibody-secreting cells) per total 1 3 10 6 lymph node cells. CD4 1 T-cell assays. 1 3 10 6 lymph node cells were cultured in a 200 ml volume with 100 mg ml 21 of OVA protein or 5 mg ml 21 of PA or 5 mg ml 21 of H5HA in 96-well round-bottomed plates for 4 days. Cells were transferred to anti-CD3 (10 mg ml 21 ) and anti-CD28 (2 mg ml 21 ) coated flat-bottomed 96-well plates for 6 h in the presence of Golgi Plug (1 mg ml 21 ) (BD Biosciences). Cells were stained for surface CD4 using PerCP anti-mouse CD4 (clone RM4-5) for 30 min at 4 uC. Cells were washed 3 times with FACS buffer, fixed and permeabilized using BD Cytofix/Cytoperm and stained for intracellular IFN-c using APC-conjugated antimouse IFN-c (clone XMG1.2) for 30 min in 13 BD perm/wash solution at 4 uC. Cells were washed with perm wash followed by FACS buffer and acquired on a
